Type 2 Diabetes Market Report Manufacturer Profiles, First-In-Class Products Have Been Assessed And Ranked According To Clinical Potential

0
56
Image Credits: https://www.sciencealert.com

Type 2 Diabetes Market Report is a proficient latest research of the Type 2 Diabetes industry comprising of leading manufacturers, product types, and market size revenue forecast. In addition, report sheds light on dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed and includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.

Request Sample of Report at: https://www.absolutereports.com/enquiry/request-sample/10070570  

Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth: Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets Report 2021 speaks about Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – high blood glucose levels – that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

View Full Report of Type 2 Diabetes market: https://www.absolutereports.com/10070570

Opportunities and Scope of Report:

The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.

  • What are the competitive advantages of the existing novel drugs?

With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.

  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the T2DM market?

Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.

  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Which patent expirations will have the most significant impact on the market?

LEAVE A REPLY